170 related articles for article (PubMed ID: 32898684)
21. Mortality Associated with Bacteremia Due to Colistin-Resistant Klebsiella pneumoniae with High-Level Meropenem Resistance: Importance of Combination Therapy without Colistin and Carbapenems.
Machuca I; Gutiérrez-Gutiérrez B; Gracia-Ahufinger I; Rivera Espinar F; Cano Á; Guzmán-Puche J; Pérez-Nadales E; Natera C; Rodríguez M; León R; Castón JJ; Rodríguez-López F; Rodríguez-Baño J; Torre-Cisneros J
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559247
[TBL] [Abstract][Full Text] [Related]
22. Inactivation of mgrB gene regulator and resistance to colistin is becoming endemic in carbapenem-resistant Klebsiella pneumoniae in Greece: A nationwide study from 2014 to 2017.
Hamel M; Chatzipanagiotou S; Hadjadj L; Petinaki E; Papagianni S; Charalampaki N; Tsiplakou S; Papaioannou V; Skarmoutsou N; Spiliopoulou I; Christofidou M; Papamichalopoulos N; Skalidis T; Legakis N; Fountoulis K; Perivolioti E; Kraniotaki H; Bournia M; Ioannidis A; Baron Sophie A; Rolain JM
Int J Antimicrob Agents; 2020 Apr; 55(4):105930. PubMed ID: 32130981
[TBL] [Abstract][Full Text] [Related]
23. Synergetic Effects of Combined Treatment of Colistin With Meropenem or Amikacin on Carbapenem-Resistant
Yu L; Zhang J; Fu Y; Zhao Y; Wang Y; Zhao J; Guo Y; Li C; Zhang X
Front Cell Infect Microbiol; 2019; 9():422. PubMed ID: 31921701
[TBL] [Abstract][Full Text] [Related]
24. Activity of Meropenem-Vaborbactam against Carbapenem-Resistant Enterobacteriaceae in a Murine Model of Pyelonephritis.
Weiss WJ; Pulse ME; Nguyen P; Peterson K; Silva J; Simecka JW; Valtierra D; Sabet M; Griffith DC
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038270
[TBL] [Abstract][Full Text] [Related]
25. Triple combination of meropenem, colistin and tigecycline was bactericidal in a dynamic model despite mere additive interactions in chequerboard assays against carbapenemase-producing Klebsiella pneumoniae isolates.
Tsala M; Vourli S; Georgiou PC; Pournaras S; Daikos GRL; Mouton JW; Meletiadis J
J Antimicrob Chemother; 2019 Feb; 74(2):387-394. PubMed ID: 30376071
[TBL] [Abstract][Full Text] [Related]
26. Emergence of colistin resistance during treatment of recurrent pneumonia caused by carbapenemase producing Klebsiella pneumoniae.
Matheeussen V; Xavier BB; Mermans I; De Weerdt A; Lammens C; Goossens H; Jansens H; Malhotra-Kumar S
Diagn Microbiol Infect Dis; 2019 Aug; 94(4):407-409. PubMed ID: 30890297
[TBL] [Abstract][Full Text] [Related]
27. Repurposing the anti-viral drug zidovudine (AZT) in combination with meropenem as an effective treatment for infections with multi-drug resistant, carbapenemase-producing strains of Klebsiella pneumoniae.
DeSarno AE; Parcell BJ; Coote PJ
Pathog Dis; 2020 Dec; 78(9):. PubMed ID: 33053176
[TBL] [Abstract][Full Text] [Related]
28. Nacubactam Enhances Meropenem Activity against Carbapenem-Resistant Klebsiella pneumoniae Producing KPC.
Barnes MD; Taracila MA; Good CE; Bajaksouzian S; Rojas LJ; van Duin D; Kreiswirth BN; Jacobs MR; Haldimann A; Papp-Wallace KM; Bonomo RA
Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31182530
[TBL] [Abstract][Full Text] [Related]
29. Meropenem-Vaborbactam as Salvage Therapy for Ceftazidime-Avibactam-Resistant
Athans V; Neuner EA; Hassouna H; Richter SS; Keller G; Castanheira M; Brizendine KD; Mathers AJ
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30578403
[TBL] [Abstract][Full Text] [Related]
30. Population Pharmacokinetics of High-Dose Continuous-Infusion Meropenem and Considerations for Use in the Treatment of Infections Due to KPC-Producing Klebsiella pneumoniae.
Cojutti P; Sartor A; Righi E; Scarparo C; Bassetti M; Pea F
Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28760900
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic strategy for pandrug-resistant Klebsiella pneumoniae severe infections: short-course treatment with colistin increases the in vivo and in vitro activity of double carbapenem regimen.
Oliva A; Mascellino MT; Cipolla A; D'Abramo A; De Rosa A; Savinelli S; Ciardi MR; Mastroianni CM; Vullo V
Int J Infect Dis; 2015 Apr; 33():132-4. PubMed ID: 25597275
[TBL] [Abstract][Full Text] [Related]
32. Study of
Zhang W; Guo Y; Yang Y; Dong D; Zheng Y; Zhu D; Hu F
Microb Drug Resist; 2020 Mar; 26(3):204-210. PubMed ID: 31553260
[No Abstract] [Full Text] [Related]
33. In vivo study assessed meropenem and amikacin combination therapy against carbapenem-resistant and carbapenemase-producing Enterobacteriaceae strains.
Hagihara M; Kato H; Yamashita R; Soda M; Watanabe H; Sakanashi D; Shiota A; Asai N; Koizumi Y; Suematsu H; Yamagishi Y; Kitaichi K; Mikamo H
J Infect Chemother; 2020 Jan; 26(1):1-7. PubMed ID: 31735629
[TBL] [Abstract][Full Text] [Related]
34. In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study).
Kazmierczak KM; Tsuji M; Wise MG; Hackel M; Yamano Y; Echols R; Sahm DF
Int J Antimicrob Agents; 2019 Feb; 53(2):177-184. PubMed ID: 30395986
[TBL] [Abstract][Full Text] [Related]
35. In vitro evaluation of double carbapenem and colistin combinations against OXA-48, NDM carbapenemase-producing colistin-resistant Klebsiella pneumoniae strains.
Erdem F; Abulaila A; Aktas Z; Oncul O
Antimicrob Resist Infect Control; 2020 May; 9(1):70. PubMed ID: 32430058
[TBL] [Abstract][Full Text] [Related]
36. Colistin resistance superimposed to endemic carbapenem-resistant Klebsiella pneumoniae: a rapidly evolving problem in Italy, November 2013 to April 2014.
Monaco M; Giani T; Raffone M; Arena F; Garcia-Fernandez A; Pollini S; ; Grundmann H; Pantosti A; Rossolini GM
Euro Surveill; 2014 Oct; 19(42):. PubMed ID: 25358041
[TBL] [Abstract][Full Text] [Related]
37. Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
Bulik CC; Christensen H; Li P; Sutherland CA; Nicolau DP; Kuti JL
Antimicrob Agents Chemother; 2010 Feb; 54(2):804-10. PubMed ID: 19995927
[TBL] [Abstract][Full Text] [Related]
38. Time kill-assays of antibiotic combinations for multidrug resistant clinical isolates of OXA-48 carbapenemase producing Klebsiella pneumoniae.
Erdem F; Díez-Aguilar M; Oksuz L; Kayacan C; Abulaila A; Oncul O; Morosini MI; Cantón R; Aktas Z
Acta Microbiol Immunol Hung; 2022 Sep; 69(3):215-219. PubMed ID: 35895557
[TBL] [Abstract][Full Text] [Related]
39. Might real-time pharmacokinetic/pharmacodynamic optimisation of high-dose continuous-infusion meropenem improve clinical cure in infections caused by KPC-producing Klebsiella pneumoniae?
Pea F; Della Siega P; Cojutti P; Sartor A; Crapis M; Scarparo C; Bassetti M
Int J Antimicrob Agents; 2017 Feb; 49(2):255-258. PubMed ID: 28012683
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of antimicrobial combinations against colistin-resistant carbapenemase (KPC)-producing Klebsiella pneumoniae.
Maraki S; Papadakis IS
J Chemother; 2015; 27(6):348-52. PubMed ID: 25248023
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
